Personalised medicine, batch size of ONE, the new challenge to fill-finish?
Wenzel Novak PhD gives some considerations on container, environment, process and automation for small batch sizes in the downstream process of fill-finish…
List view / Grid view
Articles
Formulation Development & Delivery In-Depth Focus
In this Formulation Development & Delivery In-Depth Focus: A report on the use of freeze-drying to develop orally disintegrating tablets; a review of mucosal drug delivery; an interview on drug delivery through the skin; and a profile of three analytical technologies used to develop drug delivery systems...
Scientific Poster Gallery 2017
In this supplement, we've brought together a collection of interesting posters from leading companies in order to celebrate cutting-edge research in the pharmaceutical industry and to share with our readers some of the varied work being carried out by their colleagues...
Issue #3 2017 – Digital version
In Issue #3 2017: In-Depth Focuses covering Raman Spectroscopy, Separations & Purifications, Formulation Development & Delivery; Guide To Testing Services; GMP and mutual recognition; Regulatory Insight; RMMs; Microbiology Series; and much more...
83% of life science leaders believe blockchain will be adopted within 5 years
Just under a quarter (22%) of life science companies already using or experimenting with blockchain, but industry collaboration over security and storage standards is needed…
Shire on Haemophilia: How to treat a bleeding disorder
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
Risk, benefit or cost: What stops patients from receiving a diagnostic test?
Diagnostic tests can help identify disease and disease probability in patients, leading to earlier treatment, but what’s the real cost?
Analytical techniques for faster development of drug delivery systems
The challenge of efficiently delivering a drug to its site of action, while maintaining its efficacy and minimising its potential toxicity, has received much attention in recent years, with the growing use of complex and often delicate biological molecules as therapeutic agents...
Shashank Jain on formulation for drug delivery via the skin
EPR Editor Steve Bremer discusses drug delivery through the skin with Shashank Jain, Formulation Research Scientist at G&W Laboratories.
Mucosal delivery – is this the next level in drug delivery?
Following the introduction of the concept of mucoadhesion in the 1980s, polymeric excipients became attractive for intense research purposes. Mucosal delivery as a non-invasive delivery pathway raised the bar.
Pharma Digitalisation: Challenges and opportunities in transforming the pharma industry
30 May 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Digitalisation and Sammeli Liikkanen, Chief Digital Officer, Orion Pharma
Pharma Digitalisation Executive Consultant, Pasi Kemppainen, and Orion’s CDO Sammeli Liikkanen talk technologies, challenges and opportunities with the digitalisation of pharma…
Why biosimilars are changing the pharmaceutical industry
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
Treating multiple myeloma: An interview with Janssen
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...
Behind the numbers: The pharmaceutical industry and global health
10 May 2017 | By Cristina Arnés, IFPMA Policy Analyst, Regulatory Policy and Economic Affairs
IFPMA's top analyst examines future trends, biotherapeutics and personalised medicine, and explains why the industry needs to examine its economic footprint...
Biosimilars: the future of Pharma? An interview with Boehringer Ingelheim
3 May 2017 | By Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim
With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…
